Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted ...

Maria Hordinsky, MD, discusses exciting results in alopecia areata, including some discussed at the Winter Clinical Dermatology Conference. In an interview with The American Journal of Managed Care, ...

FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...

In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists ...

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...

Data analysis reveals a stable, cross-cohort female cancer mortality excess at ages 35-60, contrasting with female advantages in cardiovascular and external-cause mortality. Breast cancer drives the ...

Rural residence is associated with higher advanced-stage (III/IV) diagnosis rates than non-rural cohorts (13.6% vs 12.1%), indicating persistent screening and diagnostic access gaps. Non-Hispanic ...

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.

Navigator models, particularly cross-specialty nurse navigation, reduce stress, expedite diagnosis-to-treatment transitions, and support participation in trials designed around transportation, work ...

Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

NHANES 2017–2018 elastography data (n=4102) linked to mortality showed 59 deaths over ~24 months; decedents were older and more likely to have diabetes. MASLD (CAP ≥274 dB/m) with diabetes carried ...